Nova Southeastern University Office of Academic Affairs Search NSU Site Map Nova Southeastern University
President's Faculty R & D Grant 
Committees, Councils
  and Boards
Faculty Policy Manual
NSU Scholarly Journals
Professional Journals
Prof. Memberships
Academic Policies & Procedures
Provost's Research and Scholarship Award
President's Faculty
 R & D Grant
PFRDG Application Review Process by NSU Librarians
Office of Academic Quality, Assessment, and Accreditation
Contact Us

Print this page  


With a focus on learning, we employ a range of strategies to support innovation, collaboration across centers, and university-wide discussion and decision-making


Ninth Annual Grant Winners 2008-2009

Dean Robert Uchin, D.D.S. (HPD-DEN)

Mitzi Palazzolo, D.D.S., M.S. (HPD-DEN)
Cesar Migliorati, D.D.S., Ph.D. (HPD-DEN)
Michael Siegel, D.D.S. (HPD-DEN)
Steven Kaltman, D.M.D., M.D. (HPD-DEN)

Helena Hellman (HPD-DEN)

Title: Risk of Bisphosphonate-Associated Osteonecrosis (BON) Following Dental Extraction


Grant Winners 2008-2009

Bisphosphonates are potent inhibitors of osteoclastic activity. Oral formulations include the aminobisphosphonates alendronate (Fosamax®), residronate (Actonel®) and ibandronate (Boniva®) which are used for the prevention and treatment of osteoporosis. Several millions of these compounds are prescribed each year. Intravenous bisphosphonates are used in patients with multiple myeloma, Paget’s disease of bone and patients with breast, prostate or lung cancer that has metastasized to bone. The most common IV formulations are zoledronic acid (Zometa®) and pamidronate (Aredia®). Amongst several adverse events associated with the use of bisphosphonates, bisphosphonate-associated osteonecrosis (BON) was recently recognized as a new oral complication in patients with cancer and osteoporosis. First reported in 2003, BON is defined as the unexpected appearance of exposed necrotic bone anywhere in the oral cavity of an individual receiving a bisphosphonate and who has not received radiation to the head and neck. Bisphosphonates accumulate over extended periods of time in mineralized bone matrix. Depending on the duration of treatment and the specific bisphosphonate prescribed, the drug could potentially remain in the body for years. The development of BON increases with time of use and antiresorptive potency of the drug. Dental extractions and oral surgery have been associated with the development of BON. The role of other factors like systemic and oral co-morbidities, other therapeutic drugs (chemotherapy, corticosteroids, etc) is unknown. There are no scientifically based recommendations for the routine dental management of patients treated with bisphosphonates. The goal of this prospective study is to evaluate outcomes of dental extractions in patients taking bisphosphonates. This information is lacking in the literature and will allow for additional guidelines on dental management. This project will be instrumental in developing a systematic way of assessing the risk of developing BON.